Vir has a promising pipeline, and expects to report data this year on several phase 2 clinical trials. Vir's revenue rose by 133.4% last year. The Food and Drug Administration recently made a decision ...

Vir signed a “landmark” collaboration with Astellas to advance VIR-5500, receiving $315 million upfront ( $240M cash + $75M equity) and becoming eligible for up to $1.37 billion in milestones, with a ...

Vir Biotechnology's coronavirus treatment is losing steam. The company's pipeline looks somewhat promising on first glance. But the biotech's most recent data readout was not encouraging. This could ...

GSK is walking away from a core piece of its $345 million bet on Vir Biotechnology. The partners have ended their collaboration on anti-influenza antibodies, freeing Vir to “actively” pitch the ...

Vir Biotechnology is narrowing its focus. Sitting on $1.9 billion, the infectious disease specialist has decided to stop work on its innate immunity small-molecule platform as part of its efforts to ...

UKRAINE - 2022/01/23: In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Shares for Vir Biotechnology climbed by nearly 30% ...

Vir Das won over the internet on Sunday with a heartwarming gesture for his fan, who waited for two years to watch him perform live. The actor-comedian shared a screenshot on his Instagram feed on ...

Vir Biotechnology and Astellas entered a license agreement to co-develop and commercialize Vir's prostate cancer treatment. The agreement is for VIR-5500, a dual-masked T-cell engager targeting ...

On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a ...